Research Analysts Offer Predictions for STERIS Q1 Earnings

STERIS plc (NYSE:STE) – Equities research analysts at Zacks Research lifted their Q1 2026 earnings per share (EPS) estimates for STERIS in a research note issued on Tuesday, February 25th. Zacks Research analyst R. Department now anticipates that the medical equipment provider will post earnings of $2.31 per share for the quarter, up from their prior estimate of $2.27. The consensus estimate for STERIS’s current full-year earnings is $9.08 per share. Zacks Research also issued estimates for STERIS’s Q2 2026 earnings at $2.36 EPS, Q1 2027 earnings at $2.62 EPS, Q2 2027 earnings at $2.69 EPS, Q3 2027 earnings at $2.81 EPS and FY2027 earnings at $10.72 EPS.

STERIS (NYSE:STE) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $2.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.33 by ($0.01). STERIS had a return on equity of 13.91% and a net margin of 8.66%.

A number of other analysts have also recently weighed in on the stock. Needham & Company LLC reiterated a “hold” rating on shares of STERIS in a research note on Friday, November 8th. Piper Sandler increased their target price on shares of STERIS from $260.00 to $265.00 and gave the stock an “overweight” rating in a research note on Monday, February 3rd. Stephens reissued an “overweight” rating and set a $240.00 price target on shares of STERIS in a report on Thursday, February 6th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $265.00 price objective on shares of STERIS in a research note on Thursday, February 6th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $258.75.

STERIS Stock Performance

Shares of STE opened at $219.89 on Thursday. The company’s 50 day simple moving average is $214.45 and its 200-day simple moving average is $223.13. The firm has a market cap of $21.60 billion, a PE ratio of 46.69 and a beta of 0.84. STERIS has a 12-month low of $197.82 and a 12-month high of $248.24. The company has a current ratio of 2.13, a quick ratio of 1.40 and a debt-to-equity ratio of 0.32.

Institutional Trading of STERIS

Several hedge funds and other institutional investors have recently made changes to their positions in STE. Franklin Resources Inc. lifted its position in STERIS by 171.2% in the third quarter. Franklin Resources Inc. now owns 838,569 shares of the medical equipment provider’s stock valued at $191,370,000 after purchasing an additional 529,308 shares during the period. Assetmark Inc. lifted its holdings in shares of STERIS by 24.6% in the 3rd quarter. Assetmark Inc. now owns 13,410 shares of the medical equipment provider’s stock valued at $3,252,000 after buying an additional 2,647 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of STERIS by 30.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,970 shares of the medical equipment provider’s stock valued at $2,275,000 after buying an additional 2,583 shares in the last quarter. KBC Group NV grew its holdings in STERIS by 52.0% during the third quarter. KBC Group NV now owns 12,071 shares of the medical equipment provider’s stock worth $2,928,000 after acquiring an additional 4,132 shares during the period. Finally, Wilmington Savings Fund Society FSB acquired a new position in STERIS during the third quarter worth $9,949,000. Hedge funds and other institutional investors own 94.69% of the company’s stock.

STERIS Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, March 21st. Stockholders of record on Thursday, February 20th will be paid a $0.57 dividend. This represents a $2.28 annualized dividend and a dividend yield of 1.04%. The ex-dividend date of this dividend is Thursday, February 20th. STERIS’s dividend payout ratio (DPR) is presently 48.41%.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.